Abstracts tagged "Pregnancy and takayasu arteritis"

Abstract Number: 2434 • 2018 ACR/ARHP Annual Meeting
Obstetric Outcomes in Women with Takayasu Arteritis: Results from Nationwide Inpatient Sample Database 2003-2011
Shweta Kishore¹, Varun Mittal² and Vikas Majithia¹, ¹Division of Rheumatology, University of Mississippi, Jackson, MS, ²University of Mississippi, Jackson, MS
Background/Purpose: Few case reports and series suggest adverse pregnancy outcomes in patients with Takayasu Arteritis (TA). This study was undertaken to determine the frequency of…
Abstract Number: 3071 • 2015 ACR/ARHP Annual Meeting
Takayasu’s Arteritis and Pregnancy
Cloé Comarmond¹, Tristan Mirault², Lucie Biard³, Jacky Nizard⁴, Marc Lambert⁵, Bertrand Wechsler⁶, Eric Hachulla⁵, Laurent Chiche⁷, Fabien Koskas⁸, Julien Gaudric⁹, Philippe Cluzel¹⁰, Emmanuel Messas¹¹, Mathieu Resche Regon¹², Jean-Charles Piette¹³, Patrice Cacoub¹³ and David Saadoun¹⁴, ¹DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ²Service de Médecine Vasculaire HEGP, Paris, France, ³Biostatistics, Saint-Louis Hospital, Paris, France, ⁴Department of obstetrics and gynaecology, Pitié-Salpêtrière Hospital, Paris, France, ⁵CHU Lille, Lille, France, ⁶Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, ⁷Service de Chirurgie Vasculaire, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, ⁸Department of Internal Medicine and 2Laboratory I3 « Immunology, Immunopathology, Immunotherapy », UMR CNRS 7211, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France, ⁹Department of Vascular surgery GHPS, Paris, France, ¹⁰Cadiovascular Imaging and Interventional Radiology, Pitié-Salpétrière, Paris, France, ¹¹HEGP hospital Vascular and cardiology Department, paris, France, ¹²biostatistics Saint Louis Hospital, paris, France, ¹³Department of Internal Medicine, Pitié-Salpêtrière Hospital, Paris, France, ¹⁴Department of Internal Medicine and clinical Immunology. French National Reference Center for Autoimmune Diseases. DHU I2B (Inflammation, Immunotherapy and Biotherapy), UPMC, Paris VI, Hôpital Pitié Salpétrière, AP-HP, UPMC, Univ Paris 06, Paris, France
Background/Purpose: To assess the relation between Takayasu's arteritis (TA) and pregnancy outcome. Methods: This study included 240 pregnancies in 96 patients fulfilling ACR and/or Ishikawa…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].